International Journal of Nephrology / 2011 / Article / Tab 3

Review Article

ADPKD: Prototype of Cardiorenal Syndrome Type 4

Table 3

Clinical trials for ADPKD.

Start-finish dateInterventionActionDesign

HALT-ADPKD STUDY (NCT00283686)2006–2013ACE inhibitors and ARBs (singly or in combination)Reduce the rate of increase in kidney volume and slow the decline in GFRMulticenter, randomized, placebo controlled
NCT004289482007–2011V2 receptor antagonist (Tolvaptan)Reduce the concentrations of cAMP and slow the progression of renal enlargementMulticenter, double blind, placebo controlled
NCT003092832006–2010Long-acting somatostatin (octreotide)Inhibit the growth of the polycystic kidneys and liverRandomized Single Center, Single blind, Placebo controlled
NCT004261532007–2010 (open-label extention)Long-acting somatostatin (octreotide)Inhibit the growth of the polycystic kidneys and liverDouble blind, Randomized, Placebo controlled, Crossover
NCT005650972007–2009 (open-label extention)Long-acting somatostatin (lanreotide)Inhibit the growth of the polycystic kidneys and liverDouble blind, Randomized, Placebo controlled
Trials with target mTORmTOR inhibitors (sirolimus, everolimus)Modulate disease progression and development of renal cysts

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.